Table 2. Effects of exercise intervention on the inflammatory factors in diabetes patients.

Items	CT group (n = 20)		IT group (n = 22)		Control group (n = 20)
	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment
TLR4 mRNA	1.68 ± 0.29**	0.77 ± 0.18	1.85 ± 0.31**	0.54 ± 0.63**Δ	1.05 ± 0.18
NF-κBp65mRNA	1.28 ± 0.26**	1.01 ± 0.11	1.41 ± 1.77**	0.86 ± 0.66Δ	0.86 ± 0.12
TLR4 protein	0.95 ± 0.34**	0.67 ± 0.33*	0.86 ± 0.25**	0.41 ± 0.16Δ	0. 45 ± 0.17
NF-κBp65 protein	0.88 ± 0.36**	0.64 ± 0.25*	0.85 ± 0.24**	0.49 ± 0.21ΔΔ	0.45 ± 0.21
YKL40	0.41 ± 0.11	0.34 ± 0.21	0.31 ± 0.14	0. 28 ± 0.09	0.27 ± 0.11
IL-18	0.80 ± 0.12**	0.72 ± 0.12*	0.81 ± 0.09**	0.51 ± 0.10Δ	0.59 ± 0.31
PTX3	0.63 ± 0.13	0.63 ± 0.14	0.64 ± 0.15	0.58 ± 0.08	0.54 ± 0.78
IL-33	0.40 ± 0.09**	0.65 ± 0.12*	0.42 ± 0.14**	0.85 ± 0.14*ΔΔ	1.38 ± 0.19

Data are mean ± SD, *p < 0.05, **p < 0.01 vs. control group; ^Δp < 0.05, ^ΔΔp < 0.01 vs. conventional therapy group. CT group: the conventional therapy group; IT group: the intensive therapy group; IL-18: interleukin-18; IL-33: interleukin-33; NF-κBp65: Nuclear factor-κBp65; PTX3: pentraxin-related protein 3; TLR4: Toll-like receptor 4; YKL40: human cartilage glycoprotein 39